Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A1 | P46059 | 1/20 | 0.57 |
| ▸ | ALPI | P09923 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.56 |
| ▸ | XIAP | P98170 | 1/20 | 0.56 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.56 |
| ▸ | MMP2 | P08253 | 3/20 | 0.52 |
| ▸ | CTSC | P53634 | 1/20 | 0.52 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | BACE1 | P56817 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26199086 | 0.90 | OPRD1 (0.53) | SLC15A1ALPIPKMPTGS1XIAP | |
| SCHEMBL21010316 | 0.86 | SLC15A1 (0.64) | SLC15A1ALPIPKMPTGS1XIAP | |
| SCHEMBL3112297 | 0.86 | ALPI (0.54) | SLC15A1ALPIPKMPTGS1XIAP | |
| SCHEMBL15590804 | 0.86 | ALPI (0.54) | SLC15A1ALPIPKMPTGS1XIAP | |
| SCHEMBL23933886 | 0.84 | ALPI (0.53) | SLC15A1ALPIPKMPTGS1XIAP | |
| SCHEMBL17844273 | 0.83 | ALPI (0.68) | SLC15A1ALPIPKMPTGS1XIAP | |
| SCHEMBL27590236 | 0.82 | SLC15A1 (0.58) | SLC15A1ALPIPKMPTGS1XIAP | |
| SCHEMBL28969894 | 0.82 | SLC15A1 (0.58) | SLC15A1ALPIPKMPTGS1XIAP | |
| SCHEMBL8195275 | 0.81 | ALPI (0.61) | SLC15A1ALPIPKMPTGS1XIAP | |
| SCHEMBL5594394 | 0.81 | ALPI (0.61) | SLC15A1ALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3953463-A1 | STABILIZED GLYCOSIDE HYDROLASE VARIANTS | Novozymes A/S (DK) | 2022-02-16 | — | — | EP | disclosed |
| US-20190352341-A1 | MODIFIED PEPTIDES AND THEIR USE FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | IMMUPHARMA FRANCE SA (FR) | 2019-11-21 | — | — | US | disclosed |
| WO-2018097999-A1 | COMPOSITIONS AND METHODS FOR MODULATING PROTEASE ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352341-A1 | MODIFIED PEPTIDES AND THEIR USE FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | SSB, LNPEP, ENPP2 | SLC15A1 2304/4885ALPI 4138/4885PKM 3496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.